Osteoporosis Drugs Market to cross USD 10.8 Billion by 2022 with Top Industry Vendors like F. Hoffmann La Roche Ltd., Pfizer Inc., Novo Nordisk, Teva Pharmaceutical Industries Ltd. and others

The market driving factors were identified to be rise in the geriatric population, increased screening, drug induced osteoporosis, alcoholism and smoking, increased awareness and focus towards female health, rising prevalence of diseases, conditions and medical procedures that may cause bone loss such as cancer, autoimmune disorders, thalassemia, hormonal disorders, modern lifestyle etc.

The market restraints are loss of patents of block busters, greater penetration of generics and fragmentation of market, poor efficacy and side effects of present therapies, non-life threatening nature and poor symptoms of osteoporosis etc.

Taking all the factors into consideration, we expect the global osteoporosis market which totaled ~ $10,855 million to reach 14,300 million by 2022, growing with a CAGR of 4.7%.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/2479

Osteoporosis is weakening of bones due to lower bone mass resulting in and micro-architectural deterioration of bone tissue and subsequent higher risk of a broken fracture. It generally occurs at an advanced age and women are more susceptible to it than males by about three to four folds. WHO estimates that around 1.66 million hip fractures occur each year worldwide due to osteoporosis. According to national osteoporosis foundation about 54 million Americans suffer from osteoporosis.

The disease also has a genetic bias in that it Caucasians are more affected than Asians. The disease prevalence is lowest in African population.

Key Players:

• Eli Lilly and Company
• Merck & Co.
• Novartis International AG
• Amgen Inc.
• F. Hoffmann La Roche Ltd.
• Pfizer Inc.
• Novo Nordisk
• Teva Pharmaceutical Industries Ltd

Segmentation:

Global osteoporosis drugs market has been segmented on the basis of drug class which comprises bisphosphonates, calcitonin’s, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others. On the basis of route of administration; market is segmented into oral, injectable and others. On the basis of gender the market is segmented into male and female.

Regional Analysis
Globally America is the largest market for osteoporosis drugs. Europe is the second-largest market for osteoporosis drugs. The developed regions are expected to hold their market leadership in the near future but with falling market share due to rise of Asia Pacific region which is expected to be fastest growing region in osteoporosis drugs market. The Asia pacific region will be led by China and India. Africa is expected to be a laggard in the global osteoporosis market.

Intended Audience:

• Osteoporosis Drugs Manufacturers
• Osteoporosis Drugs Suppliers
• Private Research Laboratories
• Research and Development (R&D) Companies
• Market Research and Consulting Service Providers
• Government Research Laboratories
• Contract Manufacturing Organizations

Browse Complete 84 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/osteoporosis-drugs-market-2479

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.